A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Trial Profile

A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Nitrite (Primary)
  • Indications Burkholderia cepacia infections; Pseudomonal infections; Staphylococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 According to an Arch Biopartners media release, company is funding the study, contributing the AB569 inhalation clinical drug kits produced by Dalton and other materials to support the trial.
    • 28 Sep 2017 According to an Arch Biopartners media release, this trial is expecting to begin at the end of 2017 or early January 2018.
    • 13 Apr 2017 Dr. Ralph Panos is the lead investigator of this trial, according to an Arch Biopartners media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top